• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Study Purpose

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1.
  • - At least 1 lesion accessible for biopsy.
  • - Eastern Cooperative Oncology Group Performance Status of 0 or 1.

Exclusion Criteria:

  • - Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll) - Participants with active, known or suspected autoimmune disease.
  • - Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration.
  • - Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS) - Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy.
Other protocol defined inclusion/exclusion criteria could apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03400332
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Bristol-Myers Squibb
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Australia, Belgium, Canada, France, Germany, Italy, Poland, Spain, Sweden, Switzerland, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Cancer, Melanoma
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Part 1A: BMS-986253 + nivolumab

Experimental: Part 1B: BMS-986253 + nivolumab

Experimental: Part 1C: BMS-986253 + nivolumab + ipilimumab

Experimental: Part 2A: BMS-986253 + nivolumab + ipilimumab

Placebo Comparator: Part 2B: Placebo + nivolumab + ipilimumab

Interventions

Drug: - BMS-986253

Specified dose on specified days

Biological: - Nivolumab

Specified dose on specified days

Biological: - Ipilimumab

Specified dose on specified days

Other: - Placebo

Specified dose on specified days

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Local Institution - 0059, Springdale 4132093, Arkansas 4099753

Status

Address

Local Institution - 0059

Springdale 4132093, Arkansas 4099753, 72762

Local Institution - 0099, Los Angeles 5368361, California 5332921

Status

Address

Local Institution - 0099

Los Angeles 5368361, California 5332921, 90033

Local Institution - 0007, Lakewood 5427946, Colorado 5417618

Status

Address

Local Institution - 0007

Lakewood 5427946, Colorado 5417618, 80228

Local Institution - 0087, Atlanta 4180439, Georgia 4197000

Status

Address

Local Institution - 0087

Atlanta 4180439, Georgia 4197000, 30322

Local Institution - 0100, Atlanta 4180439, Georgia 4197000

Status

Address

Local Institution - 0100

Atlanta 4180439, Georgia 4197000, 30342

Local Institution - 0101, Marietta 4207783, Georgia 4197000

Status

Address

Local Institution - 0101

Marietta 4207783, Georgia 4197000, 30060

Local Institution - 0012, Columbia 4352053, Maryland 4361885

Status

Address

Local Institution - 0012

Columbia 4352053, Maryland 4361885, 21044

Local Institution - 0003, Lutherville 4361379, Maryland 4361885

Status

Address

Local Institution - 0003

Lutherville 4361379, Maryland 4361885, 21093

Local Institution - 0060, Boston 4930956, Massachusetts 6254926

Status

Address

Local Institution - 0060

Boston 4930956, Massachusetts 6254926, 02215

Local Institution - 0004, Ann Arbor 4984247, Michigan 5001836

Status

Address

Local Institution - 0004

Ann Arbor 4984247, Michigan 5001836, 48109

Local Institution - 0076, Omaha 5074472, Nebraska 5073708

Status

Address

Local Institution - 0076

Omaha 5074472, Nebraska 5073708, 68130

Comprehensive Cancer Centers Of Nevada, Las Vegas 5506956, Nevada 5509151

Status

Address

Comprehensive Cancer Centers Of Nevada

Las Vegas 5506956, Nevada 5509151, 89169

Local Institution - 0005, Hackensack 5098706, New Jersey 5101760

Status

Address

Local Institution - 0005

Hackensack 5098706, New Jersey 5101760, 07601

Local Institution - 0032, New Brunswick 5101717, New Jersey 5101760

Status

Address

Local Institution - 0032

New Brunswick 5101717, New Jersey 5101760, 08903

Local Institution - 0025, New York 5128581, New York 5128638

Status

Address

Local Institution - 0025

New York 5128581, New York 5128638, 10029

Local Institution - 0002, New York 5128581, New York 5128638

Status

Address

Local Institution - 0002

New York 5128581, New York 5128638, 10032

Local Institution - 0028, Oklahoma City 4544349, Oklahoma 4544379

Status

Address

Local Institution - 0028

Oklahoma City 4544349, Oklahoma 4544379, 73104

Local Institution - 0017, Eugene 5725846, Oregon 5744337

Status

Address

Local Institution - 0017

Eugene 5725846, Oregon 5744337, 97401

Local Institution - 0001, Pittsburgh 5206379, Pennsylvania 6254927

Status

Address

Local Institution - 0001

Pittsburgh 5206379, Pennsylvania 6254927, 15213

Local Institution - 0009, Greenville 4580543, South Carolina 4597040

Status

Address

Local Institution - 0009

Greenville 4580543, South Carolina 4597040, 29615

Local Institution - 0011, Austin 4671654, Texas 4736286

Status

Address

Local Institution - 0011

Austin 4671654, Texas 4736286, 78705

Local Institution - 0010, Dallas 4684888, Texas 4736286

Status

Address

Local Institution - 0010

Dallas 4684888, Texas 4736286, 75246

Local Institution - 0014, Fort Worth 4691930, Texas 4736286

Status

Address

Local Institution - 0014

Fort Worth 4691930, Texas 4736286, 76104-3927

Local Institution - 0018, Houston 4699066, Texas 4736286

Status

Address

Local Institution - 0018

Houston 4699066, Texas 4736286, 77030

Local Institution - 0006, San Antonio 4726206, Texas 4736286

Status

Address

Local Institution - 0006

San Antonio 4726206, Texas 4736286, 78240

Local Institution - 0013, Tyler 4738214, Texas 4736286

Status

Address

Local Institution - 0013

Tyler 4738214, Texas 4736286, 75702

Local Institution - 0058, Salt Lake City 5780993, Utah 5549030

Status

Address

Local Institution - 0058

Salt Lake City 5780993, Utah 5549030, 84112

Local Institution - 0015, Fairfax 4758023, Virginia 6254928

Status

Address

Local Institution - 0015

Fairfax 4758023, Virginia 6254928, 22031

Local Institution - 0008, Norfolk 4776222, Virginia 6254928

Status

Address

Local Institution - 0008

Norfolk 4776222, Virginia 6254928, 23502

International Sites

Local Institution - 0088, Wollstonecraft 9972972, New South Wales 2155400, Australia

Status

Address

Local Institution - 0088

Wollstonecraft 9972972, New South Wales 2155400, 2065

Local Institution - 0096, Adelaide 2078025, South Australia 2061327, Australia

Status

Address

Local Institution - 0096

Adelaide 2078025, South Australia 2061327, 5000

Local Institution - 0090, Melbourne 2158177, Victoria 2145234, Australia

Status

Address

Local Institution - 0090

Melbourne 2158177, Victoria 2145234, 3000

Local Institution - 0095, Melbourne 2158177, Victoria 2145234, Australia

Status

Address

Local Institution - 0095

Melbourne 2158177, Victoria 2145234, 3004

Local Institution - 0097, Perth 2063523, Western Australia 2058645, Australia

Status

Address

Local Institution - 0097

Perth 2063523, Western Australia 2058645, 6009

Local Institution - 0091, Ballarat Central 8014922, Australia

Status

Address

Local Institution - 0091

Ballarat Central 8014922, , VIC 3350

Local Institution - 0037, Brussels 2800866, Belgium

Status

Address

Local Institution - 0037

Brussels 2800866, , 1200

Local Institution - 0036, Ghent 2797656, Belgium

Status

Address

Local Institution - 0036

Ghent 2797656, , 9000

Local Institution - 0082, Kortrijk 2794055, Belgium

Status

Address

Local Institution - 0082

Kortrijk 2794055, , 8500

Local Institution - 0030, Edmonton 5946768, Alberta 5883102, Canada

Status

Address

Local Institution - 0030

Edmonton 5946768, Alberta 5883102, T6G 1Z2

Local Institution - 0029, Vancouver 6173331, British Columbia 5909050, Canada

Status

Address

Local Institution - 0029

Vancouver 6173331, British Columbia 5909050, V5Z 4E6

Local Institution - 0078, Victoria 6174041, British Columbia 5909050, Canada

Status

Address

Local Institution - 0078

Victoria 6174041, British Columbia 5909050, V8R 6V5

Local Institution - 0020, Toronto 6167865, Ontario 6093943, Canada

Status

Address

Local Institution - 0020

Toronto 6167865, Ontario 6093943, M5G 1Z5

Local Institution - 0055, Toronto 6167865, Ontario 6093943, Canada

Status

Address

Local Institution - 0055

Toronto 6167865, Ontario 6093943, M5G 2M9

Local Institution - 0056, Montreal 6077243, Quebec 6115047, Canada

Status

Address

Local Institution - 0056

Montreal 6077243, Quebec 6115047, H2X 0A9

Local Institution - 0067, Marseille 2995469, Bouches-du-Rhône, France

Status

Address

Local Institution - 0067

Marseille 2995469, Bouches-du-Rhône, 13385

Local Institution - 0085, Nantes 2990969, France

Status

Address

Local Institution - 0085

Nantes 2990969, , 44000

Local Institution - 0068, Paris 2988507, France

Status

Address

Local Institution - 0068

Paris 2988507, , 75010

Local Institution - 0102, Toulouse 2972315, France

Status

Address

Local Institution - 0102

Toulouse 2972315, , 31059

Local Institution - 0069, Villejuif 2968705, France

Status

Address

Local Institution - 0069

Villejuif 2968705, , 94800

Local Institution - 0054, Tübingen 2820860, Baden-Wurttemberg 2953481, Germany

Status

Address

Local Institution - 0054

Tübingen 2820860, Baden-Wurttemberg 2953481, 72076

Local Institution - 0052, Mainz 2874225, Rhineland-Palatinate 2847618, Germany

Status

Address

Local Institution - 0052

Mainz 2874225, Rhineland-Palatinate 2847618, 55131

Local Institution - 0034, Berlin 2950159, Germany

Status

Address

Local Institution - 0034

Berlin 2950159, , 12200

Local Institution - 0053, Hamburg 2911298, Germany

Status

Address

Local Institution - 0053

Hamburg 2911298, , 20251

Local Institution - 0043, Forlì 3176746, Italy

Status

Address

Local Institution - 0043

Forlì 3176746, , 47014

Local Institution - 0042, Milan 6951411, Italy

Status

Address

Local Institution - 0042

Milan 6951411, , 20132

Local Institution - 0027, Napoli 9031661, Italy

Status

Address

Local Institution - 0027

Napoli 9031661, , 80131

Local Institution - 0026, Rozzano-milano, Italy

Status

Address

Local Institution - 0026

Rozzano-milano, , 20089

Local Institution - 0071, Krakow 3094802, Poland

Status

Address

Local Institution - 0071

Krakow 3094802, , 31-115

Local Institution - 0077, Warsaw 756135, Poland

Status

Address

Local Institution - 0077

Warsaw 756135, , 02-781

Local Institution - 0045, Madrid 3117735, Spain

Status

Address

Local Institution - 0045

Madrid 3117735, , 28034

Local Institution - 0022, Madrid 3117735, Spain

Status

Address

Local Institution - 0022

Madrid 3117735, , 28040

Local Institution - 0023, Madrid 3117735, Spain

Status

Address

Local Institution - 0023

Madrid 3117735, , 28050

Local Institution - 0044, Málaga 2514256, Spain

Status

Address

Local Institution - 0044

Málaga 2514256, , 29010

Local Institution - 0021, Pamplona 3114472, Spain

Status

Address

Local Institution - 0021

Pamplona 3114472, , 31008

Local Institution - 0047, Santiago de Compostela 3109642, Spain

Status

Address

Local Institution - 0047

Santiago de Compostela 3109642, , 15706

Local Institution - 0049, Lund 2693678, Sweden

Status

Address

Local Institution - 0049

Lund 2693678, , 221 85

Local Institution - 0040, Lausanne 2659994, Switzerland

Status

Address

Local Institution - 0040

Lausanne 2659994, , 1011

Local Institution - 0041, Sankt Gallen 2658822, Switzerland

Status

Address

Local Institution - 0041

Sankt Gallen 2658822, , 9007

Local Institution - 0039, Zurich 2657896, Switzerland

Status

Address

Local Institution - 0039

Zurich 2657896, , 8091

Local Institution - 0024, Manchester 2643123, Greater Manchester, United Kingdom

Status

Address

Local Institution - 0024

Manchester 2643123, Greater Manchester, M20 4BX

Local Institution - 0083, Glasgow 2648579, Lanarkshire, United Kingdom

Status

Address

Local Institution - 0083

Glasgow 2648579, Lanarkshire, G12 0YN

Local Institution - 0019, Birmingham 2655603, West Midlands, United Kingdom

Status

Address

Local Institution - 0019

Birmingham 2655603, West Midlands, B15 2TH

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact